Although the tyrosine kinase inhibitor (TKI) against BCR-ABL, imatinib, is the first-line therapy for CML, acquired resistance almost inevitably emerges. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.